Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Shang‐Gin Wu's publication output changed over time?
ScholarIQpublication output · 2008–2020
Output declined50% over the shown period — from 2 works in 2008 to 1 in 2020.
2
1
1
1
1
1
2
1
1
200820102011201220142015201620182020
What are the most-cited papers on Shang‐Gin Wu?
ScholarIQmost cited works
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
Shang‐Gin Wu, Jin‐Yuan Shih
S132829192. 2018829 CitationsOPEN ACCESS
Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response
Jenn‐Yu Wu, Shang‐Gin Wu, Chih-Hsin Yang, Chien‐Hung Gow, Yih‐Leong Chang, Chong‐Jen Yu, Jin‐Yuan Shih, Pan‐Chyr Yang
Clinical Cancer Research. 2008323 CitationsOPEN ACCESS
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
Shang‐Gin Wu, Yinan Liu, Meng‐Feng Tsai, Yih‐Leong Chang, Chong‐Jen Yu, Pan‐Chyr Yang, James Chih‐Hsin Yang, Yueh‐Feng Wen, Jin‐Yuan Shih
Oncotarget. 2016237 CitationsOPEN ACCESS
Survival of lung adenocarcinoma patients with malignant pleural effusion
Shang‐Gin Wu, Chong‐Jen Yu, Meng‐Feng Tsai, Wei‐Yu Liao, Chih-Hsin Yang, I‐Shiow Jan, Pan‐Chyr Yang, Jin‐Yuan Shih
S4210207896. 201294 CitationsOPEN ACCESS
EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR
Shang‐Gin Wu, Yao-Wen Kuo, Yih‐Leong Chang, Jin‐Yuan Shih, Yahui Chen, Meng‐Feng Tsai, Chong‐Jen Yu, Chih-Hsin Yang, Pan‐Chyr Yang
Journal of Thoracic Oncology. 201190 CitationsOPEN ACCESS
Related on ScholarIQ
National Taiwan University
Institution
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
Paper
Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response
Paper
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
Paper
Survival of lung adenocarcinoma patients with malignant pleural effusion
Paper
EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR
Paper